Navigation Links
Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
Date:6/5/2011

EAST HANOVER, N.J., June 5, 2011 /PRNewswire/ -- Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

The results show that at five years 66% of patients taking Gleevec for three years remained free of cancer recurrence (primary endpoint) compared to 48% who had received Gleevec for only one year (p<0.0001). Moreover, 92% of patients taking Gleevec for three years were alive (secondary endpoint) compared to 82% who had received Gleevec for only one year (p=0.019) (1). Median patient follow-up was 54 months.

The 400-patient Phase III trial, conducted by the Scandinavian Sarcoma Group (SSG) and the Sarcoma Group of the Arbeitsgemeinschaft Internistische Onkologie (AIO), is the first prospective multicenter clinical trial to demonstrate a survival benefit of adjuvant Gleevec therapy for KIT+ GIST with extended three years of therapy relative to one year of therapy. The side effect profile in the clinical trial was consistent with that reported in previous studies with Gleevec.

"This study confirms the hypothesis that extending the duration of Gleevec treatment for patients following surgery improves recurrence-free survival. For the first time, an effect on overall survival was found," said Heikki Joensuu, M.D., Ph.D., Professor, Oncology, University of Helsinki and principal investigator of the study. "Results from this trial may positively impact clinical practice by helping physicians create the optimal treatment plan for patients with operable KIT+ GIST."

Gastrointestinal stromal tumors are a rare, life-threatening cancer of the gastrointestinal
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
2. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
3. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
4. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
5. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
6. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
7. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
8. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
9. Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
10. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
11. Final Approval of Novartis Gender Discrimination Settlement Slated for November 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... MT. PROSPECT, Ill. , June 18, 2013 ... availability of its new X3130 Appliance Inlet Module. ... thermal circuit breaker , combines a C14 appliance ... in one compact package.  This three-in-one device allows ... in their designs - cutting installation time by ...
(Date:6/18/2013)... N.J. , June 18, 2013  Actavis, Inc. (NYSE: ... Actavis") has filed with the U.S. Securities and Exchange Commission ... Actavis, proposed acquisition of Warner Chilcott plc (NASDAQ: ... of Actavis and Warner Chilcott (the "Form S-4"). ... and Warner Chilcott have entered into a definitive ...
(Date:6/18/2013)... , June 18, 2013  It has ... of Alliance Seating and Mobility, a subsidiary company ... access timely repair. This appears to be due ... reduction of field service employees.  ... great many of these clients are complex mobility ...
Breaking Medicine Technology:Three-in-One X3130 Appliance Inlet Module 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7
... 21, 2010 Takeda Pharmaceutical Company Limited ("Takeda") ... Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed ... against the companies in response to their Abbreviated ... HCl), ACTO plus met® (pioglitazone HCl and ...
... Dec. 21, 2010 Today, Pepex Biomedical, Inc. announced ... $244,479.25 under the Qualifying Therapeutic Discovery Project created by ... Affordable Care Act of 2010, the major health care ... March 23, 2010.  Pepex submitted their ground-breaking, patented, electrochemical ...
Cached Medicine Technology:Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 2Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 3Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 4Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 5Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 6Pepex™ Awarded Qualifying Therapeutic Discovery Project Grant 2
(Date:6/18/2013)... Palo Alto has taken yet another step in ... its recent major long-term solar power commitment. , Last ... power purchase agreements , which together will result in the ... electric power per year, which is the equivalent of roughly ... power to supply all 65,000+ Palo Alto residents---and then some! ...
(Date:6/18/2013)... New York, NY (PRWEB) June 18, 2013 ... M2a Magnum hip continue to move forward in a ... Indiana, Bernstein Liebhard LLP reports. According to court ... on June 17th, at which time the Court also ... scientific and technical issues pertinent to the Biomet hip ...
(Date:6/18/2013)... June 18, 2013 Sun Buick GMC, Moosic, ... Health Services 20th Annual Golf Tournament on Thursday, June 20, ... hole-in-one prize is a 2013 Buick Verano and will go ... a hole-in-one on Irem’s 7th hole. , The MFHS golf ... is a four person captain and crew team for 18 ...
(Date:6/18/2013)... 18, 2013 Seven-year-old Riley Salz of ... autism. He receives 40 hours a week of applied ... from the Center for Autism and Related Disorders (CARD). ... 2008, and has experienced remarkable progress, including learning to ... environment. Riley’s personal journey through autism is now featured ...
(Date:6/18/2013)... 18, 2013 Internationally acclaimed plastic ... website, thebestbreast.com, showcasing his unique approach to breast ... about his surgical method and highlights the results ... his website, Dr. Tebbetts compares his breast augmentation ... Dr. Tebbetts’ method does not necessitate the use ...
Breaking Medicine News(10 mins):Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 3Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2
... M. Miano, Ph.D associate professor within the Cardiovascular Research ... that // small regulatory DNA sequences control ... scanned the vast human DNA code to reveal 60 ... of the study were published in the journal Genome ...
... one of the National Institutes of Health has awarded ... Infectious Disease Agent Study (MIDAS) grants to // ... research team. , The goal of this ... techniques. These techniques would be used later to quickly ...
... treatment benefits with your doctor does not seems to benefit ... Colleagues, University of California, San Francisco found in a study ... and shared the decision with their doctor. ,The ... patient did not benefit the patient in deciding the symptoms ...
... has revealed that investing more money in the country’s healthcare ... necessarily// result in better services. The manner in which the ... the author of the report. The name of the report ... healthcare system in the country is available at British Columbia, ...
... for rotavirus has been approved by the US. The rotavirus ... of about 500,000 children across the world annually. // In ... medicine's maker tested the vaccine on more than 70,000 children ... ,Rotavirus is a highly contagious virus that causes severe dehydrating ...
... will be recruiting Indian nurses to overcome the shortage of ... Nursing at Medi-Clinic, told the Afrikaans daily Beeld here that ... for India to start a selection process for 60 clinical ... project in the Western Cape Province, where the shortage of ...
Cached Medicine News:Health News:Human Complexity Can Be Attributed To Regulatory Sequence 2Health News:Detecting Epidemics using statistics 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: